A molecular assay of tumor radiosensitivity: A roadmap towards biology-based personalized radiation therapy

Personalized Medicine

Volumn 9, Issue 5, 2012, Pages 547-557

  Torres Roca, Javier F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

gene expression; molecular signatures; radiation therapy; radiosensitivity; systems biology

Indexed keywords

CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PANITUMUMAB; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA BINDING PROTEIN 4;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL DECISION MAKING; COLORECTAL CANCER; DEACETYLATION; DNA DAMAGE; GENE EXPRESSION; GENE REARRANGEMENT; GENOMICS; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; LOCAL RECURRENCE FREE SURVIVAL; LUNG NON SMALL CELL CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; RECTUM CARCINOMA; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; SYSTEMS BIOLOGY;

EID: 84864492966     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.55     Document Type: Article

References (72)

1. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 104(6), 1129-1137 (2005). (Pubitemid 41278947)
2. Lievens Y, Grau C. Health economics in radiation oncology: introducing the ESTRO HERO project. Radiother. Oncol. 103, 109-112 (2012).
3. Bentzen SRM, Heeren G, Cottier B et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffng needs in Europe: the ESTRO QUARTS project. Radiother. Oncol. 75(3), 355-365 (2005). (Pubitemid 41007983)
4. Sher DJ. Cost-effectiveness studies in radiation therapy. Expert Rev. Pharmacoecon. Outcomes Res. 10(5), 567-582 (2010).
5. Verellen D, De Ridder M, Linthout N, Tournel K, Soete G, Storme G. Innovations in image-guided radiotherapy. Nat. Rev. Cancer 7(12), 949-960 (2007). (Pubitemid 350165868)
6. Bucci MK, Bevan A, Roach M 3rd. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J. Clin. 55(2), 117-134 (2005). (Pubitemid 40372906)
7. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J. Clin. Oncol. 28(10), 1684-1691 (2010).
8. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modifed radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J. Clin. Oncol. 29(21), 2852-2858 (2011).
9. Peters LJ. The ESTRO Regaud lecture. Inherent radio sensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother. Oncol. 17(3), 177-190 (1990). (Pubitemid 20110265)
10. Peters LJ, Brock WA, Chapman JD, Wilson G. Predictive assays of tumor radiocurability. Am. J. Clin. Oncol. 11(3), 275-287 (1988).
11. Torres-Roca JF, Stevens C W. Predicting response to clinical radiotherapy: past, present, and future directions. Cancer Control 15(2), 151-156 (2008).
12. West CM, Davidson SE, Roberts SA, Hunter RD. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br. J. Cancer 68(4), 819-823 (1993). (Pubitemid 23301293)
13. West CM, Davidson SE, Roberts SA, Hunter RD. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br. J. Cancer 76(9), 1184-1190 (1997). (Pubitemid 27448015)
14. Buffa FM, Davidson SE, Hunter RD, Nahum AE, West CM. Incorporating biologic measurements (SF(2), CFE) into a tumor control probability model increases their prognostic signifcance: a study in cervical carcinoma treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 50(5), 1113-1122 (2001). (Pubitemid 32727787)
15. Bjork-Eriksson T, West C, Karlsson E, Mercke C. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 46(1), 13-19 (2000). (Pubitemid 30021473)
16. Stausbol-Gron B, Overgaard J. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck. Radiother. Oncol. 50(1), 47-55 (1999). (Pubitemid 29136738)
17. Taghian A, Ramsay J, Allalunis-Turner J et al. Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 25(2), 243-249 (1993). (Pubitemid 23048776)
18. Eschwege F, Bourhis J, Girinski T et al. Predictive assays of radiation response in patients with head and neck squamous cell carcinoma: a review of the Institute Gustave Roussy experience. Int. J. Radiat. Oncol. Biol. Phys. 39(4), 849-853 (1997). (Pubitemid 27489525)
19. 2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary fndings. Urology 60(4), 634-639 (2002). (Pubitemid 35246449)
20. Fyles A, Milosevic M, Hedley D et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol. 20(3), 680-687 (2002). (Pubitemid 34111374)
21. Begg AC, Haustermans K, Hart AA et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother. Oncol. 50(1), 13-23 (1999). (Pubitemid 29136733)
22. Bourhis J, Dendale R, Hill C et al. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks. Int. J. Radiat. Oncol. Biol. Phys. 35(3), 471-476 (1996). (Pubitemid 26242894)
23. Corvo R, Giaretti W, Sanguineti G et al. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J. Clin. Oncol. 13(8), 1843-1850 (1995).
24. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J. Clin. 61(2), 91-112 (2011).
25. Krause M, Baumann M. Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer Metastasis Rev. 27(3), 387-402 (2008).
26. Van De Vijver MJ, He YD, Van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002). (Pubitemid 35461656)
27. Van't Veer LJ, Dai H, Van De Vijver MJ et al. Gene expression profling predicts clinical outcome of breast cancer. Nature 415 (6871), 530-536 (2002). (Pubitemid 34130608)
28. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004). (Pubitemid 40051905)
29. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab effcacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
30. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and beneft from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359(17), 1757-1765 (2008).
31. Mitsudomi T, Morita S, Yatabe Y et al. Geftinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11(2), 121-128 (2010).
32. Maemondo M, Inoue A, Kobayashi K et al Geftinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380-2388 (2010).
33. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12(11), 1004-1012 (2011).
34. Beer DG, Kardia SL, Huang CC et al. Gene-expression profles predict survival of patients with lung adenocarcinoma. Nat. Med. 8(8), 816-824 (2002).
35. Chung CH, Parker JS, Karaca G et al Molecular classifcation of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5(5), 489-500 (2004). (Pubitemid 38610250)
36. Eschrich S, Yang I, Bloom G et al. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23(15), 3526-3535 (2005).
37. Pawitan Y, Bjohle J, Amler L et al. Gene expression profling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 7(6), R953-R964 (2005).
38. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460), 671-679 (2005). (Pubitemid 40260888)
39. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 306(5696), 640-643 (2004). (Pubitemid 39440903)
40. Hood L, Perlmutter RM. The impact of systems approaches on biological problems in drug discovery. Nat. Biotech. 22(10), 1215-1217 (2004). (Pubitemid 39336768)
41. Kitano H. Systems biology: a brief overview. Science 295(5560), 1662-1664 (2002). (Pubitemid 34202893)
42. Kitano H. Computational systems biology Nature 420(6912), 206-210 (2002). (Pubitemid 35340131)
43. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc. Natl Acad Sci. USA 104(21), 8685-8690 (2007). (Pubitemid 47175372)
44. Torres-Roca JF, Eschrich S, Zhao H et al. Prediction of radiation sensitivity using a gene expression classifer. Cancer Res. 65(16), 7169-7176 (2005). (Pubitemid 41161247)
45. Eschrich S, Zhang H, Zhao H et al. Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int. J. Radiat. Oncol. Biol. Phys. 75(2), 497-505 (2009).
46. Russell JS, Brady K, Burgan WE et al Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 63(21), 7377-7383 (2003). (Pubitemid 37413479)
47. Ma BBY, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J. Clin. Oncol. 21(14), 2760-2776 (2003). (Pubitemid 46613486)
48. Cerna D, Camphausen K, Toflon PJ. Histone deacetylation as a target for radiosensitization. Curr. Top. Dev. Biol. 73, 173-204 (2006). (Pubitemid 43878133)
49. Milas L, Mason KA, Liao Z, Ang KK. Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 25(2), 152-167 (2003). (Pubitemid 36133895)
50. Kaminski JM, Hanlon AL, Joon DL, Meistrich M, Hachem P, Pollack A. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int. J. Radiat. Oncol. Biol. Phys. 57(1), 24-28 (2003). (Pubitemid 36959735)
51. Deng X, Hofmann Er, Villanueval A et al. Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Nature Genet. 36(8), 906-912 (2004). (Pubitemid 39014112)
52. Hallahan DE, Dunphy E, Kuchibhotla J, Kraft A, Unlap T, Weichselbaum RR. Prolonged c-jun expression in irradiated ataxia telangiectasia fbroblasts. Int. J. Radiat. Oncol. Biol. Phys. 36(2), 355-360 (1996). (Pubitemid 26359461)
53. Kao GD, Mckenna WG, Muschel RJ. p34(Cdc2) kinase activity is excluded from the nucleus during the radiation-induced G(2) arrest in HeLa cells. J. Biol. Chem. 274(49), 34779-34784 (1999). (Pubitemid 129509521)
54. Li N, Karin M. Ionizing radiation and short wavelength UV activate NF-kappa B through two distinct mechanisms. Proc. Natl Acad. Sci. USA 95(22), 13012-13017 (1998). (Pubitemid 28509515)
55. Liu J, Yang D, Minemoto Y, Leitges M, Rosner MR, Lin A. NF-kappaB is required for UV-induced JNK activation via induction of PKCdelta. Molecular Cell 21(4), 467-480 (2006). (Pubitemid 43228003)
56. Fryknäs M, Dhar S, Oberg F et al. STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. Int. J. Cancer 120(1), 189-195 (2007). (Pubitemid 44901935)
57. Nakajima T, Yukawa O, Azuma C et al. Involvement of protein kinase C-related anti-apoptosis signaling in radiation-induced apoptosis in murine thymic lymphoma (3SBH5) cells. Radiat. Res. 161(5), 528-534 (2004). (Pubitemid 40754221)
58. Pamment J, Ramsay E, Kelleher M, Dornan D, Ball KL. Regulation of the IRF-1 tumour modifer during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 21(51), 7776-7785 (2002). (Pubitemid 35398835)
59. Terzoudi Gi, Jung T, Hain J et al. Increased G2 chromosomal radiosensitivity in cancer patients: the role of cdk1/cyclin-B activity level in the mechanisms involved. Int. J. Radiat. Biol. 76(5), 607-615 (2000). (Pubitemid 30345161)
60. Wang QE, Zhu Q, Wani G, El-Mahdy MA, Li J, Wani AA. DNA repair factor XPC is modifed by SUMO-1 and ubiquitin following UV irradiation. Nucleic Acids Res. 33(13), 4023-4034 (2005). (Pubitemid 41487263)
61. Marples B, Collis SJ. Low-dose hyper-radiosensitivity: past, present, and future. Int. J. Radiat. Oncol. Biol. Phys. 70(5), 1310-1318 (2008). (Pubitemid 351417777)
62. Lindsay KJ, Coates PJ, Lorimore SA, Wright EG. The genetic basis of tissue responses to ionizing radiation. Br. J. Radiol. 80 Spec No 1, S2-S6 (2007). (Pubitemid 47517793)
63. Starmans MH, Zips D, Wouters BG, Baumann M, Lambin P. The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. Radiother. Oncol. 92(3), 417-422 (2009).
64. Eschrich SA, Pramana J, Zhang H et al. A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 75(2), 489-496 (2009).
65. Torres Roca JF, Fulp WJ, Pawitan Y et al. RSI: a novel biomarker predicts RT therapeutic beneft in breast cancer. Program and Abstracts of ASTRO 53rd Annual Meeting. Miami Beach, FL, USA, 2-6 October 2011 (Abstract 122).
66. Dalton WS, Friend SH. Cancer biomarkers-an invitation to the table. Science 312(5777), 1165-1168 (2006).
67. Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol. Oncol. 1(4), 406-412 (2008).
68. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351(17), 1731-1740 (2004).
69. O'Neill BD, Brown G, Heald RJ, Cunningham D, Tait DM. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol. 8(7), 625-633 (2007). (Pubitemid 47008889)
70. Habr-Gama A, Perez Ro, Nadalin W et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann. Surg. 240(4), 711-717; discussion 717-718 (2004).
71. Maas M, Beets-Tan RG, Lambregts DM et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J. Clin. Oncol. 29(35), 4633-4640 (2011).
72. Butcher EC, Berg EL, Kunkel EJ. Systems biology in drug discovery. Nature Biotech. 22(10), 1253-1259 (2004). (Pubitemid 39336778)